Scholarlink

<p>Delayed platele<!--Query ID="Q1" Text="Please check and confirm if the authors and their respective affiliations are correctly identified and amend if necessary." Resolved="yes"-->t engraftment (DPE) is a prevalent complication following umbilical cord blood transplantation (UCBT), accompanied by increased transplant-related mortality. This study aims to evaluate the efficacy, safety, and tolerability of romiplostim and recombinant human thrombopoietin (rhTPO) in enhancing platelet engraftment after UCBT. A total of 19 patients scheduled to receive UCBT were randomly assigned to the romiplostim group (250&#xa0;µg once weekly from day 5 to platelet engraftment after UCBT, <i>n</i> = 7) or rhTPO group (300 U/kg once daily from days 5 to 18 after UCBT, <i>n</i> = 12). The median time of PLT engraftment was no statistical difference between rhTPO and romiplostim group: 29.5 days (range: 13–43 days) compared to 31 days (range: 23–40 days; <i>P</i> =.269). The median dose of romiplostim was 4 (range: 2–5 doses). Furthermore, the consumption of PLT was equivalent between the Ro group and the rhTPO group: 10 units (range: 7–26 units) and 10 units (range: 3–24 units; <i>P</i> =.694). All patients survived for one year and remained relapse-free. Romiplostim group had a lower incidence of acute graft versus host disease (aGvHD). No severe adverse effects were observed in any of the patients. This study demonstrated that romiplostim and rhTPO are both effective in promoting platelet engraftment after UCBT. Romiplostim was more practical and tolerable due to its cost and labor-saving benefits.<!--Query ID="Q2" Text="Please check and confirm if authors'Tiantian Sun and Yin Wang' captured as corresponding authors is correct, and please provide email address. Otherwise, please amend" Resolved="yes"--></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Romiplostim versus Recombinant human thrombopoietin in umbilical cord blood transplantation: a single-center retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月9日

查看全文
  • Yuntian Ding,
  • Hengyu Liu,
  • Yaqun Wang,
  • Haimei Deng,
  • Yanfeng Sun,
  • Tiantian Sun,
  • Yin Wang,
  • Yunxin Zeng

摘要

Delayed platelet engraftment (DPE) is a prevalent complication following umbilical cord blood transplantation (UCBT), accompanied by increased transplant-related mortality. This study aims to evaluate the efficacy, safety, and tolerability of romiplostim and recombinant human thrombopoietin (rhTPO) in enhancing platelet engraftment after UCBT. A total of 19 patients scheduled to receive UCBT were randomly assigned to the romiplostim group (250 µg once weekly from day 5 to platelet engraftment after UCBT, n = 7) or rhTPO group (300 U/kg once daily from days 5 to 18 after UCBT, n = 12). The median time of PLT engraftment was no statistical difference between rhTPO and romiplostim group: 29.5 days (range: 13–43 days) compared to 31 days (range: 23–40 days; P =.269). The median dose of romiplostim was 4 (range: 2–5 doses). Furthermore, the consumption of PLT was equivalent between the Ro group and the rhTPO group: 10 units (range: 7–26 units) and 10 units (range: 3–24 units; P =.694). All patients survived for one year and remained relapse-free. Romiplostim group had a lower incidence of acute graft versus host disease (aGvHD). No severe adverse effects were observed in any of the patients. This study demonstrated that romiplostim and rhTPO are both effective in promoting platelet engraftment after UCBT. Romiplostim was more practical and tolerable due to its cost and labor-saving benefits.